Pioneers in the Field of 
  Cardiac Gene Therapy

Pioneers in the Field of 
    Cardiac Gene Therapy

Why Sardocor

A UNIQUE APPROACH TO

CARDIAC GENE THERAPY

A UNIQUE APPROACH TO

CARDIAC GENE THERAPY

A UNIQUE APPROACH TO

CARDIAC GENE THERAPY


Sardocor is dedicated to the clinical development of novel therapies for patients with devastating common and rare diseases.

  • Foundational science by pioneers who established the field of cardiac gene therapy 3 decades ago.

  • Using Novoheart's bioengineered human heart-based assays for disease modelling and therapeutic discovery.

  • Sardocor aspires to create the shortest regulatory path to effective next-generation gene therapies.

  • Proprietary delivery method to the heart for enhancing effectiveness and reducing side effects.
Call Us Now

Sardocor at a glance

No IV's

No IV's

No Toxicity

No Toxicity

Highly targeted therapy

Highly Targeted

No Immunogenicity

No Immunogenicity

Our Clinical Trials

Sardocor has obtained open Investigational New Drug (IND) approvals from The United States Food and Drug Administration (FDA) for three gene therapy clinical trials.

Farming
Heart Failure with reduced Ejection Fraction (HFrEF)

Heart Failure with reduced Ejection Fraction (HFrEF)

Farming
Heart Failure with preserved Ejection Fraction (HFpEF)

Heart Failure with preserved Ejection Fraction (HFpEF)

Agriculture
Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD)

Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM)

Pioneering Delivery

> 1,000 doses of SRD001 have been manufactured and been made available to patients.

Our proprietary intracoronary delivery method to infuse gene therapy drug right into the heart has been uniquely designed to use the least amount drugs for efficacy while avoiding side effects.

Cardiac gene therapy research

Investors

JOIN A GROUP OF

REVOLUTIONARY STARTERS

Sardocor is on the lookout for investor relationships that can mutually benefit

 our science, propel innovation and investment.

bioengineered human heart-based assays for disease modelling
Share by: